Trial Profile
A Randomized, Double-Blind, Dosing-Ranging, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Antroquinonol (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Golden Biotechnology Corporation
- 11 Sep 2023 Status changed from recruiting to completed.
- 14 Mar 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 14 Mar 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.